Sale of MC Diagnostics to ACT Genomics
Deal Type: Sale
Deal Size: Not Disclosed
Seneca Corporate Finance acted as lead advisor to the shareholders of MC Diagnostics on the sale to international firm, ACT Genomics.
ACT Genomics is entering the European precision medicine market with the acquisition of MCD which specialises in the design and development of molecular diagnostics across the fields of immunogenetics, immunology, blood banking and microbiology.
The companies have partnered to develop fusion genechips on MCD’s ALDAS platform, from which tests can now be performed at the point of care.